Oak Ridge Investments LLC Supernus Pharmaceuticals, Inc. Transaction History

Oak Ridge Investments LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 05, 2020	SELL	$19.93 - $29.13 $2.42 Million - $3.54 Million	-121,504 Closed	0 $0
Q3 2019 Nov 07, 2019	SELL	$25.47 - $33.37 $282,793 - $370,507	-11,103 Reduced 8.37%	121,504 $3.34 Million
Q2 2019 Aug 14, 2019	SELL	$29.96 - $38.87 $490,355 - $636,185	-16,367 Reduced 10.99%	132,607 $4.39 Million
Q1 2019 May 09, 2019	BUY	$32.77 - $41.99 $73,240 - $93,847	2,235 Added 1.52%	148,974 $5.22 Million
Q4 2018 Feb 11, 2019	SELL	$30.84 - $49.51 $530,972 - $852,413	-17,217 Reduced 10.5%	146,739 $4.88 Million
Q3 2018 Nov 07, 2018	SELL	$42.7 - $56.55 $739,862 - $979,841	-17,327 Reduced 9.56%	163,956 $8.26 Million
Q2 2018 Aug 13, 2018	SELL	$44.1 - $59.85 $827,271 - $1.12 Million	-18,759 Reduced 9.38%	181,283 $10.9 Million
Q1 2018 May 14, 2018	SELL	$37.15 - $46.9 $2.25 Million - $2.84 Million	-60,634 Reduced 23.26%	200,042 $9.16 Million
Q4 2017 Feb 13, 2018	BUY	$36.4 - $42.6 $3.13 Million - $3.67 Million	86,104 Added 49.32%	260,676 $10.4 Million
Q3 2017 Nov 07, 2017	BUY	$36.75 - $49.65 $6.42 Million - $8.67 Million	174,572	174,572 $6.98 Million

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.92B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Oak Ridge Investments LLC, based on Form 13F filings with the SEC.

Stay updated on Oak Ridge Investments LLC with notifications on news.